Korean Medication Algorithm Project for Bipolar Disorder 2022:Rapid Cycling
10.4306/jknpa.2022.61.3.204
- Author:
Jong-Hyun JEONG
1
;
Won-Myong BAHK
;
Young Sup WOO
;
Bo-Hyun YOON
;
Jeong Seok SEO
;
IL Han CHOO
;
Chan-Mo YANG
;
Won KIM
;
Jung Goo LEE
;
Se-Hoon SHIM
;
Sung-Yong PARK
;
InKi SOHN
;
Moon-Doo KIM
;
Myung Hun JUNG
;
Duk-In JON
Author Information
1. Department of Psychiatry, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Korean Neuropsychiatric Association
2022;61(3):204-213
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:This study revised the Korean Medication Algorithm Project for Bipolar Disorder 2018 for rapid cycling.
Methods:Questionnaires to survey the expert opinion of medication for rapid cycling were completed by a review committee consisting of 87 Korean expert psychiatrists. The experts’ opinions were classified into three categories based on the lowest category in which the confidence interval fell (6.5≤ for first-line, 3.5≤ for second-line, and 3.5> for third-line treatment).
Results:The first-line treatments were a combination of mood stabilizers and atypical antipsychotics, atypical antipsychotics monotherapy, or mood stabilizer monotherapy. Furthermore, a mood stabilizer with lamotrigine therapy and an atypical antipsychotic with lamotrigine combinations was the first-line treatment for a depressive episode. The first-line medications in all episodes were valproate, lithium, quetiapine, olanzapine, and aripiprazole. Risperidone was the first-line medication in manic episodes and mixed states, and lamotrigine was the first-line medication for treating depressive episodes.
Conclusion:Compared to the surveys in 2018, the preference for atypical antipsychotics and lamotrigine has increased, and the modalities as a second-line treatment are more diversified.
